How Alzheimer's Disease Progressively Destroys Memory

The Disease That Steals People Before They Die

Approximately 6.7 million Americans are living with Alzheimer's disease as of 2023, according to the Alzheimer's Association—a number projected to reach 13.8 million by 2060 as the population ages. Alzheimer's is not a normal part of aging. It is a progressive neurodegenerative disease that systematically destroys neurons, beginning in the memory centers of the brain and spreading outward until the person can no longer speak, swallow, or breathe independently. It is the seventh leading cause of death in the United States and the most expensive disease in the country, costing an estimated $345 billion annually in medical and caregiving expenses. Understanding its biology has consumed decades of research—and, for the first time, produced approved treatments that slow it.

Two Hallmarks: Plaques and Tangles

Alzheimer's disease is defined pathologically by two abnormal protein aggregations that were first described by German psychiatrist Alois Alzheimer in 1906 when he examined the brain of Auguste Deter, a 50-year-old woman who had died of what he called "a peculiar severe disease process."

Amyloid plaques: The amyloid precursor protein (APP), a normal membrane protein, is cleaved by enzymes called secretases. In Alzheimer's, beta-secretase and gamma-secretase cleave APP at positions that release a 42-amino-acid fragment called amyloid-beta 42 (Aβ42). Unlike the shorter Aβ40, this fragment is stickier and prone to aggregating into oligomers, then fibrils, and finally the dense extracellular plaques visible in post-mortem brain tissue. These plaques appear 15–20 years before symptoms.

Tau tangles: Tau is a protein that normally stabilizes microtubules—the internal transport highways of neurons. In Alzheimer's, tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into insoluble filaments that twist together inside neurons. These neurofibrillary tangles disrupt neuronal transport, eventually killing the cell. Unlike plaques, tangles appear closer to—and correlate better with—the emergence of symptoms.

Where Damage Begins: The Hippocampus

Alzheimer's does not attack the brain uniformly. It begins in a specific region: the entorhinal cortex and hippocampus, structures in the medial temporal lobe that are essential for forming new memories (a process called encoding). This is why the earliest and most characteristic symptom is difficulty learning new information—appointments, names, recent conversations—while older memories remain relatively intact.

The spread of tau pathology follows a predictable pattern, described in the Braak staging system (stages I–VI), moving from the entorhinal cortex through the limbic system, and eventually into association cortices throughout the brain. By the time the frontal lobes are heavily involved, executive function, personality, and language deteriorate severely.

The Stages of Alzheimer's Disease

Risk Factors: Genetic and Modifiable

The single largest genetic risk factor for late-onset Alzheimer's is the APOE ε4 allele. One copy of APOE ε4 increases risk roughly 3-fold compared to the most common APOE ε3 allele; two copies increase risk 8 to 12-fold. Approximately 25% of the population carries one copy, and 2–3% carry two copies. The APOE ε2 allele is associated with reduced risk.

Rare early-onset familial Alzheimer's (before age 65) can be caused by mutations in APP, PSEN1, or PSEN2 genes, but these account for fewer than 1% of all cases. The vast majority of Alzheimer's is late-onset and influenced by a combination of genetics, lifestyle, and vascular health:

• Modifiable risk factors that reduce risk: regular aerobic exercise, maintaining hearing health, treating high blood pressure, avoiding smoking, social engagement, higher educational attainment
• The 2020 Lancet Commission on dementia prevention identified 12 modifiable risk factors responsible for an estimated 40% of worldwide dementia cases

Current Treatments: A New Era Begins

For decades, Alzheimer's treatments were purely symptomatic—cholinesterase inhibitors (donepezil, rivastigmine) boost acetylcholine levels to temporarily improve cognition; memantine modulates glutamate activity. Neither slows disease progression.

In 2023, a new class of drugs—amyloid-targeting monoclonal antibodies—achieved regulatory approval:

• Lecanemab (Leqembi): FDA granted traditional approval in July 2023. In a phase 3 trial of 1,795 patients, lecanemab slowed clinical decline by 27% over 18 months compared to placebo. It targets amyloid protofibrils and clears plaques.
• Donanemab (Kisunla): FDA approved in July 2024. In its phase 3 trial, it slowed decline by 35% in patients with low-to-medium tau levels. It clears plaques so effectively that some patients can discontinue treatment once plaques are cleared.

Both drugs carry a risk of amyloid-related imaging abnormalities (ARIA)—brain swelling or microbleeds—requiring MRI monitoring. They are indicated only for early-stage disease (MCI or mild dementia) with confirmed amyloid pathology via PET scan or cerebrospinal fluid testing.

This article is for informational purposes only. Consult a qualified neurologist or healthcare provider for diagnosis and treatment of memory concerns.